Market news

Study Shows Protection Against Highly Pathogenic Clade I Mpox Virus and Durable CD8+ T-Cell Responses Findings Support GeoVax's Broader Strategy to Expand the Utility of the MVA Vaccine Platform ATLANTA, GA - September 21, 2026 (NEWMEDIAWIRE) - GeoVa...

BDBV-Specific Construct Developed Using GeoVax Proprietary Rapid Cloning Technology and Builds on Established Filovirus Vaccine Experience GEO-MVA (Mpox/Smallpox Vaccine) Targeted for Phase 3 Initiation Remains Company Priority ATLANTA, GA - Septembe...

Independent Evaluation Supports GEO-MVA Pivotal Phase 3 Program Advances GeoVax's Strategy to Expand and Diversify MVA Vaccine Supply ATLANTA, GA - September 14, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology c...

ATLANTA, GA - September 10, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers, today provided an...

Gavi-funded, ICG-Coordinated Initiative Establishes Long-Term Infrastructure for Timely and Equitable Mpox Vaccine Access During Outbreaks New Stockpile Framework Supports Sustainable Supply and Long-Term Global Preparedness ATLANTA, GA - September 9...

Detailed price information for Geovax Labs Inc (GOVX-Q) from The Globe and Mail including charting and trades.

ATLANTA, GA - August 26, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its entry into a warrant inducement agreement with an existing institutio...

Selections of CRO and European Clinical Sites Represent Significant Milestones Toward Initiation of the GEO-MVA Immunobridging Study ATLANTA, GA - August 25, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology compa...

Emerging Evidence of Potential Protection From Authorized Ebola Zaire Vaccine Against Bundibugyo Virus Provides Rationale for Evaluating GeoVax's MVA-Based Ebola Vaccine Candidates ATLANTA, GA - August 24, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nas...

Moderna-Merck Positive Phase 3 Combination Results Reinforce Strategic Rationale for Planned Gedeptin(R) + KEYTRUDA(R) Study ATLANTA, GA - August 24, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company devel...

Former Georgia Life Sciences Chair Selected for CEO Spotlight and Private Global Health Policy Roundtable With U.S. Rep. Rich McCormick ATLANTA, GA - August 20, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology co...

Company Prepared to Contribute Hemorrhagic Fever Vaccine Expertise and Candidates to Global Response Mpox/smallpox Remains Lead Infectious Disease Priority, With Broader MVA Portfolio Providing Strategic Optionality ATLANTA, GA - August 13, 2026 (NEW...

FDA Approval of Replimune's Intratumoral Therapy in Combination With Checkpoint Inhibition Reinforces Growing Momentum Behind Tumor-Directed Approaches Designed to Enhance Anti-Tumor Immune Response ATLANTA, GA - August 11, 2026 (NEWMEDIAWIRE) - GeoV...

Company Advances GEO-MVA Toward Planned Pivotal Immunobridging Study Under Expedited Regulatory Pathway ATLANTA, GA - July 27, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immu...

ASPR Report Reinforces National Priorities for Domestic Manufacturing, Platform Technologies, Strategic National Stockpile Modernization, and Pandemic Preparedness ATLANTA, GA - July 21, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clini...

Detailed price information for Geovax Labs Inc (GOVX-Q) from The Globe and Mail including charting and trades.